Evidence map›Paper›PMID 35732801›Full record

ArticleOncogene2022

Acetylation dependent translocation of EWSR1 regulates CHK2 alternative splicing in response to DNA damage.

Tianzhuo Zhang, Zhe Wang, Minghui Liu, Lu Liu, Xin Yang, Yu Zhang, Juntao Bie, Yutong Li, Mengmeng Ren, Chen Song and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 2 countries.

Tianzhuo ZhangDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Zhe WangDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Minghui LiuDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Lu LiuDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Xin YangDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Yu ZhangDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Juntao BieDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Yutong LiDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Mengmeng RenDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Chen SongDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China.
Wengong WangDepartment of Biochemistry and Biophysics, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Peking University Health Science Center, Beijing, 100191, China.ORCID 0000-0002-1720-809X
Hongyu TanDepartment of Anesthesiology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, 100142, China. maggitan@yeah.net.ORCID 0000-0002-8721-5068
Jianyuan LuoDepartment of Medical Genetics, Center for Medical Genetics, Peking University Health Science Center, Beijing, 100191, China. luojianyuan@bjmu.edu.cn.ORCID 0000-0001-6057-2914
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ewing sarcoma breakpoint region 1 (EWSR1) is a member of FET (FUS/EWSR1/TAF15) RNA-binding family of proteins. The Ewing sarcoma oncoprotein EWS-FLI1 has been extensively studied, while much less is known about EWSR1 itself, especially the potential role of EWSR1 in response to DNA damage. Here, we found that UV irradiation induces acetylation of EWSR1, which is required for its nucleoli translocation. We identified K423, K432, K438, K640, and K643 as the major acetylation sites, p300/CBP and HDAC3/HDAC10 as the major acetyltransferases and deacetylases, respectively. Mechanically, UV-induced EWSR1 acetylation repressed its interaction with spliceosomal component U1C, which caused abnormal splicing of CHK2, suppressing the activity of CHK2 in response to UV irradiation. Taken together, our findings uncover acetylation as a novel regulatory modification of EWSR1, and is essential for its function in DNA damage response.

Indexed as

Checkpoint Kinase 2DNA DamageRNA-Binding Protein EWSSarcoma, EwingAcetylationAlternative SplicingHistone DeacetylasesHumansOncogene Proteins, FusionProtein TransportCheckpoint Kinase 2CHEK2 protein, humanEWSR1 protein, humanHDAC10 protein, humanHistone DeacetylasesOncogene Proteins, FusionRNA-Binding Protein EWS

Identifiers

PMID35732801
OpenAlexW4283258313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.